ONCOCYTE PROVIDES CORPORATE UPDATE AND REPORTS FIRST QUARTER 2019 FINANCIAL RESULTS

 

Completes successful Analytical Validation study and initiates CLIA Validation study

 

On track for commercial availability of DetermaVu™ in 2H 2019

 

Conference Call Today at 4:30 PM EDT

 

ALAMEDA, Calif., May 14, 2019 —

OncoCyte Corporation (NYSE American: OCX), a developer of novel, non-invasive tests for the early detection of lung cancer, today reported financial and operating results for the first quarter ended March 31, 2019 and provided a corporate update.

 

“During the first quarter and now into the second quarter, we continued to make great strides advancing DetermaVu™ through clinical development,” commented William Annett, President and Chief Executive Officer of OncoCyte. “In addition to the previously-reported positive results of our R&D Validation study, we recently announced positive results from our Analytical Validation study of DetermaVu™. We have moved quickly into the next phase and expect to complete CLIA Laboratory Validation soon. We will then proceed to the final study before commercialization, an approximately 440 patient blinded prospective Clinical Validation study.”

 

“With each successful validation step, we are rapidly approaching commercial availability, which we anticipate in the second half of this year. In parallel, we have begun to develop plans to explore the utility of DetermaVu™ in other solid tumor cancer indications with the goal of making this novel technology available to as many patients as possible. We continue to believe that DetermaVu™, which leverages our proprietary Immune System Interrogation approach to detect subtle changes in immune biomarkers in response to early-stage cancer, is poised to change the paradigm in lung cancer diagnostics. We look forward to efficiently completing the remaining development steps and transitioning to a commercial-stage company.”

 

Highlights

 

    Successfully completed Analytical Validation and initiated CLIA Laboratory Validation study
     
  Announced a late-breaking abstract and discussion session at the American Thoracic Society 2019 International Conference detailing the compelling results from the R&D Validation study, a blinded, prospective study demonstrating best-in-class performance with sensitivity of 90% and specificity of 75%
     
    Completed a successful equity raise of $37.3 million in net proceeds which provides the funding to complete the development of DetermaVu™ and initiate commercialization efforts.
     
  On-track to complete remaining validation studies by mid-year and make DetermaVu™ commercially available in the second half of 2019

 

 
 

 

Remaining Validation Pathway for DetermaVu™:

 

  2Q 2019: CLIA Laboratory Validation study – Currently underway to rerun between 100 and 120 patient blood samples previously run in the R&D Validation study to confirm that the same positive results are obtained on the analytically validated systems in OncoCyte’s CLIA laboratory
     
  Mid-year 2019: Clinical Validation study – Will run approximately 440 blinded, prospectively-collected blood samples to establish DetermaVu™’s performance in an independent, blinded data set as a final confirmation of test sensitivity and specificity in OncoCyte’s CLIA lab setting
     
  2H 2019: Anticipated commercial availability of DetermaVu™
     
  Post-launch (2020 initiation): Clinical Utility study – Will conduct a real world evidence study to demonstrate a net improvement in patient outcomes and cost savings for the healthcare system from the use of DetermaVu™ as a confirmatory diagnostic test for lung cancer

 

First Quarter 2019 Financial Highlights

 

At March 31, 2019, OncoCyte had cash, cash equivalents and marketable securities of $39.9 million as compared to $8.4 million at December 31, 2018. The balance sheet was strengthened in February 2019 with the successful equity raise of $37.3 million in net proceeds from an underwritten public offering.

 

For the first quarter ended March 31, 2019, OncoCyte incurred a net loss of $3.9 million, or $(0.08) per share, as compared to $3.8 million, or $(0.12) per share, for the three months ended March 31, 2018.

 

Operating expenses for the three months ended March 31, 2019 were $4.0 million, and $3.2 million on an as-adjusted basis, as compared to $3.9 million, or $3.4 million on an as adjusted basis, for the same period in 2018.

 

The reconciliation between GAAP and non-GAAP operating expenses is provided in the financial tables included with this earnings release.

 

Research and development expenses for the quarter ended March 31, 2019 were $1.3 million as compared to $1.5 for the same period in 2018, relatively unchanged quarter over quarter, as OncoCyte continued to focus resources on the development and commercialization of DetermaVu™.

 

General and administrative expenses for the three months ended March 31, 2019 were $2.4 million, as compared to $1.7 million for the same period in 2018, an increase of $0.7 million. This increase is primarily attributable to $0.4 million in personnel and related expenses and $0.3 million in stock-based compensation expense due to increased grants of equity awards.

 

Sales and marketing expenses for the three months ended March 31, 2019 were $0.2 million, as compared to $0.7 million for the same period in 2018, a decrease of $0.5 million, primarily attributable to a decrease in marketing personnel and consultants as OncoCyte concentrated its resources on the development of DetermaVu™ rather than on marketing related activities.

 

 
 

 

Conference Call

 

The Company will host a conference call today, May 14, 2019, at 4:30 pm EDT / 1:30 pm PDT to discuss the results along with recent corporate developments.

 

The dial-in number in the U.S./Canada is 877-407-9716; for international participants, the number is 201-493-6779. For all callers, please refer to Conference ID 13689785. To access the live webcast, go to the investor relations section on the Company’s website, http://investors.oncocyte.com/events-and-presentations.

 

About DetermaVu™

 


DetermaVu™ is being developed as an intermediate step to confirm the absence of cancer between imaging modalities (LDCTs) detecting suspicious lung nodules and downstream invasive procedures that determine if the nodules are malignant. OncoCyte estimates that a $2 billion to $4.7 billion annual market could develop in the U.S. for its confirmatory lung cancer liquid biopsy test, depending on the scope of physician utilization, market penetration and reimbursable pricing.

 

DetermaVu™ has the potential to dramatically reduce U.S. healthcare costs by billions of dollars each year by eliminating unnecessary biopsies, which, according to a recent Medicare study, cost on average $14,634 each. In addition, DetermaVu™ can provide great benefit to patients by avoiding invasive biopsies and the complications that arise in up to 24% of those procedures, and deaths that occur in up to 1% of cases.

 

DetermaVu™ is a trademark of OncoCyte Corporation.

 

About OncoCyte Corporation

 

OncoCyte is focused on the development and commercialization of novel, non-invasive blood (“liquid biopsy”) diagnostic tests for the early detection of lung cancer. Early detection of cancer can improve health outcomes, reduce the cost of care, and improve patients’ quality of life. Liquid biopsy diagnostic tests like those OncoCyte is developing may reduce the need for costlier and riskier diagnostic procedures such as invasive biopsy procedures. OncoCyte is focusing its efforts on the development of DetermaVu™ as a non-invasive confirmatory diagnostic test for lung cancer. DetermaVu™ is being developed using proprietary sets of genetic molecular markers that differentially express in lung cancer. OncoCyte also plans to conduct research to identify additional molecular markers, acquire or license markers and related technology, and develop cancer tests based on those markers.

 

 
 

 

OncoCyte Forward Looking Statements

 

Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” and similar expressions) are forward-looking statements. These statements include those pertaining to the implementation and results of research, development, clinical trials and studies, commercialization plans, future financial and/or operating results, and future opportunities for OncoCyte, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of our third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, the need and ability to obtain future capital, and maintenance of intellectual property rights, and the need to obtain third party reimbursement for patients’ use of any diagnostic tests we commercialize. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly as such statements should be evaluated together with the many uncertainties that affect the business of OncoCyte, particularly those mentioned in the “Risk Factors” and other cautionary statements found in OncoCyte’s Securities and Exchange Commission filings. OncoCyte disclaims any intent or obligation to update these forward-looking statements, except as required by law.

 

Investor Contacts

 

Bob Yedid

LifeSci Advisors, LLC

646-597-6989

bob@lifesciadvisors.com

 

 
 

 

ONCOCYTE CORPORATION

CONDENSED BALANCE SHEETS

(IN THOUSANDS)

 

   March 31, 2019   December 31, 2018 
   (Unaudited)     
ASSETS          
CURRENT ASSETS          
Cash and cash equivalents  $39,257   $8,034 
Marketable equity securities   606    428 
Prepaid expenses and other current assets   1,130    180 
Total current assets   40,993    8,642 
           
NONCURRENT ASSETS          
Machinery and equipment, net   486    614 
Deposits and other noncurrent assets   198    262 
TOTAL ASSETS  $41,677   $9,518 
           
LIABILITIES AND SHAREHOLDERS’ EQUITY          
CURRENT LIABILITIES          
Amount due to BioTime and affiliates  $-   $2,101 
Accounts payable   136    166 
Accrued expenses and other current liabilities   1,957    2,109 
Loan payable, current   800    800 
Financing lease liability, current   304    385 
Total current liabilities   3,197    5,561 
           
NONCURRENT LIABILITIES          
Loan payable, net of deferred financing costs, noncurrent   159    347 
Financing lease liability, noncurrent   134    187 
TOTAL LIABILITIES   3,490    6,095 
           
SHAREHOLDERS’ EQUITY          
Preferred stock, no par value, 5,000 shares authorized; none issued and outstanding   -    - 
Common stock, no par value, 85,000 shares authorized; 51,973 and 40,664 shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively   113,370    74,742 
Accumulated other comprehensive loss   -    - 
Accumulated deficit   (75,183)   (71,319)
Total shareholders’ equity   38,187    3,423 
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY  $41,677   $9,518 

 

 
 

 

ONCOCYTE CORPORATION

CONDENSED STATEMENTS OF OPERATIONS

(IN THOUSANDS, EXCEPT PER SHARE DATA)

(UNAUDITED)

 

   Three Months Ended
March 31,
 
   2019   2018 
EXPENSES:          
Research and development  $1,343   $1,461 
General and administrative   2,449    1,787 
Sales and marketing   205    658 
Total operating expenses   3,997    3,906 
           
Loss from operations   (3,997)   (3,906)
           
OTHER INCOME (EXPENSES), NET          
Interest expense, net   (19)   (60)
Unrealized gain on marketable equity securities   178    190 
Other expenses, net   (26)   (2)
Total other income, net   133    128 
           
NET LOSS  $(3,864)  $(3,778)
           
Net loss per share: basic and diluted  $(0.08)  $(0.12)
           
Weighted average common shares outstanding: basic and diluted   46,647    31,676 

 

 
 

 

ONCOCYTE CORPORATION

CONDENSED STATEMENTS OF CASH FLOWS

(IN THOUSANDS)

(UNAUDITED)

 

   Three Months Ended 
   March 31, 
   2019   2018 
CASH FLOWS FROM OPERATING ACTIVITIES:          
Net loss  $(3,864)  $(3,778)
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation expense   110    103 
Amortization of intangible assets   -    61 
Amortization of prepaid maintenance   9    - 
Stock-based compensation   686    347 
Unrealized gain on marketable equity securities   (178)   (190)
Amortization of debt issuance costs   12    22 
Other   26    - 
Changes in operating assets and liabilities:          
Amount due to BioTime and affiliates   (2,101)   7 
Prepaid expenses and other current assets   (950)   (324)
Accounts payable and accrued liabilities   (468)   999 
Net cash used in operating activities   (6,718)   (2,753)
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Purchase of equipment   (7)   (5)
Security deposit and other   54    - 
Net cash provided by (used in) investing activities   47    (5)
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Proceeds from exercise of options   943    51 
Proceeds from sale of common shares   40,250    8,000 
Financing costs to issue common shares   (2,965)   - 
Repayment of loan payable   (200)   (200)
Repayment of financing lease obligations   (134)   (81)
Net cash provided by financing activities   37,894    7,770 
           
NET INCREASE IN CASH AND CASH EQUIVALENTS   31,223    5,012 
CASH AND CASH EQUIVALENTS:          
At beginning of the period   8,034    7,600 
At end of the period  $39,257   $12,612 

 

 
 

 

Non-GAAP Financial Measures

 

This earnings release includes operating expenses prepared in accordance with accounting principles generally accepted in the United States (GAAP), and includes certain historical non-GAAP operating expenses. In particular, OncoCyte has provided non-GAAP total operating expenses, adjusted to exclude noncash stock-based compensation and depreciation and amortization expense. Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable financial measures prepared in accordance with GAAP. However, OncoCyte believes the presentation of non-GAAP total operating expenses, when viewed in conjunction with our GAAP total operating expenses, is helpful in understanding OncoCyte’s ongoing operating expenses and its programs.

 

Furthermore, management uses these non-GAAP financial measures in the aggregate to establish budgets and operational goals, to manage OncoCyte’s business and to evaluate its performance and its programs.

 

OncoCyte Corporation

 

Reconciliation of Non-GAAP Financial Measure

Adjusted Operating Expenses

 

   Amounts In Thousands 
   For the Three Months Ended March 31, 2019 (unaudited) 
GAAP Operating Expenses - as reported  $3,997 
Stock-based compensation expense   (686)
Depreciation and amortization expense   (119)
Non-GAAP Operating Expenses, as adjusted  $3,192 

 

 
 

 

 


The following information was filed by Oncocyte Corp (OCX) on Tuesday, May 14, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one quarter to another to evaluate Oncocyte Corp's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Oncocyte Corp.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Log in with your credentials

or    

Forgot your details?

Create Account